Scholarlink

Introduction <p>Growth hormone (GH) deficiency (GHD) elevates high-sensitivity C-reactive protein (hs-CRP) levels, an inflammatory marker. While daily GH replacement has been shown to reduce hs-CRP levels, the effects of long-acting GH therapyon hs-CRP remain unclear.</p> Purpose <p>This pilot study aimed to investigate the association between a once-weekly GH derivative, somapacitan, and hs-CRP in adult patients with GHD.</p> Methods <p>This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.</p> Results <p>Among 13 adult patients with GHD (9 men; 10 with adult-onset GHD), serum hs-CRP levels significantly decreased following somapacitan therapy (0.24 [0.07–0.51] to 0.07 [0.06–0.25] mg/dL, <i>P</i> &lt;.001), whereas serum insulin-like growth factor (IGF)-1 levels (80 ± 53 to 148 ± 74 ng/mL, <i>P</i> &lt;.001) and IGF-1 SD scores (− 2.8 ± 2.3 to − 0.4 ± 1.7, <i>P</i> &lt;.001) significantly increased. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels showed slight but statistically insignificant decreases after the treatment. Changes in hs-CRP levels correlated significantly with changes in IGF-1 SD scores (<i>r</i> = −.66, <i>P</i> =.01), AST (<i>r</i> =.67, <i>P</i> =.01), and ALT (<i>r</i> =.74, <i>P</i> =.004). In partial correlation analyses, changes in hs-CRP levels remained significantly associated with ALT changes (<i>r</i> =.59, <i>P</i> =.04), independent of IGF-1 SD score changes.</p> Conclusion <p>The reduction in hs-CRP levels after somapacitan therapy for GHD suggests that somapacitan has a protective role against inflammation, possibly mediated by the liver.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reduced high-sensitivity C-reactive protein levels following weekly somapacitan in adults with growth hormone deficiency: a prospective pilot study

  • 期刊论文

  • 发表日期：

    2025年7月29日

查看全文
  • Yasufumi Seki,
  • Satoshi Morimoto,
  • Makiko Ikemoto,
  • Saya Takebe,
  • Saori Kitayama,
  • Kiyotaka Hirata,
  • Noriyoshi Takano,
  • Daisuke Watanabe,
  • Atsuhiro Ichihara

摘要

Introduction

Growth hormone (GH) deficiency (GHD) elevates high-sensitivity C-reactive protein (hs-CRP) levels, an inflammatory marker. While daily GH replacement has been shown to reduce hs-CRP levels, the effects of long-acting GH therapyon hs-CRP remain unclear.

Purpose

This pilot study aimed to investigate the association between a once-weekly GH derivative, somapacitan, and hs-CRP in adult patients with GHD.

Methods

This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.

Results

Among 13 adult patients with GHD (9 men; 10 with adult-onset GHD), serum hs-CRP levels significantly decreased following somapacitan therapy (0.24 [0.07–0.51] to 0.07 [0.06–0.25] mg/dL, P <.001), whereas serum insulin-like growth factor (IGF)-1 levels (80 ± 53 to 148 ± 74 ng/mL, P <.001) and IGF-1 SD scores (− 2.8 ± 2.3 to − 0.4 ± 1.7, P <.001) significantly increased. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels showed slight but statistically insignificant decreases after the treatment. Changes in hs-CRP levels correlated significantly with changes in IGF-1 SD scores (r = −.66, P =.01), AST (r =.67, P =.01), and ALT (r =.74, P =.004). In partial correlation analyses, changes in hs-CRP levels remained significantly associated with ALT changes (r =.59, P =.04), independent of IGF-1 SD score changes.

Conclusion

The reduction in hs-CRP levels after somapacitan therapy for GHD suggests that somapacitan has a protective role against inflammation, possibly mediated by the liver.